Mokshith Mannuru Advances to International Competition Against Top Students

Georgia Bio and the BioEd Institute named  Mokshith Mannuru , a junior at South Forsyth High School in Cumming, GA, as the winner of the 2022 Georgia BioGENEius Challenge. The BioGENEius Challenge is the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Mokshith will attend the 2022 International BioGENEius competition, which will be held during the 2022 BIO International Convention, the industry’s trade conference from June 13-16 in San Diego, CA. There he will engage with leading companies, scientists and innovators currently transforming the scientific landscape and gain valuable insights into an industry making significant contributions to the world.

While in San Diego, Mokshith will compete against high school students from the U.S., Canada, and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Mokshith’s project uses bioinformatics to identify the common function of genes that are related to Autism Spectrum Disorder (ASD). Over 1,000 genes are evidenced to contribute to ASD but are not understood well enough to use genetics in diagnosing or treating ASD. Mokshith hypothesized that these genes contribute to human development and would therefore affect development if a copy of the gene were faulty. He used data from the International Mouse Phenotyping Consortium (IMPC) to observe the phenotypes of mice where the ASD genes that are also found in mice were knocked out (deleted). The missing genes were found to strongly affect development or behavior, or lead to embryonic lethality. ASD patients would have one mutated copy of a gene related to ASD and one normal copy. This research suggests several pathways and development processes that attribute to ASD and could be used to validate ASD mouse models that are used in biomedical research.

“The level of competition in Georgia was at an all-time high this year,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled to have Mokshith represent our state on the international stage at the upcoming BIO Convention, and we are proud to support this Georgia scholar in his future endeavors.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Varun Sendilraj ,who is a senior at Lambert High School in Suwanee, GA. Varun developed a mobile app, DFUCare, which uses deep-learning algorithms to diagnose, analyze and monitor Diabetic Foot Ulcers (DFU) in diabetes patients. DFU is a major complication of diabetes mellitus that can lead to amputation and mortality if left untreated. Caring for DFU can be expensive and time consuming, which limits treatment options for many patients around the globe. DFUCare quantifies the size of wounds, performs tissue analysis, and detects healing potential over time. It can also allow doctors and patients to share medical reports with experts, saving time and resources for treating diabetic foot ulcers.

Judging the 2022 Georgia BioGENEius Challenge were Jamie L. Graham, Boehringer Ingelheim; Ralph L. Cordell, CDC; Ian Biggs, UGA; and Alex Harvey, ViaMune, Inc.

“I am amazed at the quality and thoughtfulness of the projects on display,” said Ian Biggs of UGA’s Innovation Gateway. “The insights displayed, and the obvious effort put into the projects is way beyond my expectations.”

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the 2022 schedule. Winners will receive cash scholarships.

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the BioEd Institute

The BioEd Institute, a division of the 501(c)(3) nonprofit the Center for Global Health Innovation, works to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. BioEd works closely with its sister organization Georgia Bio, which serves the state’s life science industry. For more information about BioEd, visit them online at  www.georgiabioed.org , or on Facebook (@GeorgiaBioEd), Twitter (@georgiabioed), or LinkedIn (@georgia-bioed).

Contacts

Kristin Boscan
585.943.8699
kboscan@cghi.org

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: